Literature DB >> 15686915

Design, synthesis, and evaluation of oxazole transthyretin amyloidogenesis inhibitors.

Hossein Razavi1, Evan T Powers, Hans E Purkey, Sara L Adamski-Werner, Kyle P Chiang, Maria T A Dendle, Jeffery W Kelly.   

Abstract

Ten oxazoles bearing a C(4) carboxyl group were synthesized and evaluated as transthyretin (TTR) amyloid fibril inhibitors. Substituting aryls at the C(2) position of the oxazole ring reveals that a 3,5-dichlorophenyl substituent significantly reduced amyloidogenesis. The efficacy of these inhibitors was enhanced further by installing an ethyl, a propyl, or a CF(3) group at the C(5) position. The CF(3) substitution at C(5) also improves the TTR binding selectivity over all the other proteins in human blood.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15686915     DOI: 10.1016/j.bmcl.2004.12.022

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  15 in total

1.  A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin.

Authors:  Sungwook Choi; Jeffery W Kelly
Journal:  Bioorg Med Chem       Date:  2010-12-30       Impact factor: 3.641

Review 2.  Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis.

Authors:  Susan L Lindquist; Jeffery W Kelly
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-12-01       Impact factor: 10.005

3.  Aromatic sulfonyl fluorides covalently kinetically stabilize transthyretin to prevent amyloidogenesis while affording a fluorescent conjugate.

Authors:  Neil P Grimster; Stephen Connelly; Aleksandra Baranczak; Jiajia Dong; Larissa B Krasnova; K Barry Sharpless; Evan T Powers; Ian A Wilson; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2013-02-14       Impact factor: 15.419

Review 4.  Current and future treatment of amyloid diseases.

Authors:  M Ankarcrona; B Winblad; C Monteiro; C Fearns; E T Powers; J Johansson; G T Westermark; J Presto; B-G Ericzon; J W Kelly
Journal:  J Intern Med       Date:  2016-05-10       Impact factor: 8.989

5.  Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.

Authors:  Stephen Connelly; David E Mortenson; Sungwook Choi; Ian A Wilson; Evan T Powers; Jeffery W Kelly; Steven M Johnson
Journal:  Bioorg Med Chem Lett       Date:  2017-05-26       Impact factor: 2.823

Review 6.  The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug.

Authors:  Steven M Johnson; Stephen Connelly; Colleen Fearns; Evan T Powers; Jeffery W Kelly
Journal:  J Mol Biol       Date:  2012-01-05       Impact factor: 5.469

7.  Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis.

Authors:  Nora S Green; Ted R Foss; Jeffery W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-29       Impact factor: 11.205

Review 8.  Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses.

Authors:  Stephen Connelly; Sungwook Choi; Steven M Johnson; Jeffery W Kelly; Ian A Wilson
Journal:  Curr Opin Struct Biol       Date:  2010-02-03       Impact factor: 6.809

9.  Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies.

Authors:  Steven M Johnson; Stephen Connelly; Ian A Wilson; Jeffery W Kelly
Journal:  J Med Chem       Date:  2008-09-24       Impact factor: 7.446

10.  Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors.

Authors:  Teresa Mairal; Joan Nieto; Marta Pinto; Maria Rosário Almeida; Luis Gales; Alfredo Ballesteros; José Barluenga; Juan J Pérez; Jesús T Vázquez; Nuria B Centeno; Maria Joao Saraiva; Ana M Damas; Antoni Planas; Gemma Arsequell; Gregorio Valencia
Journal:  PLoS One       Date:  2009-01-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.